220 related articles for article (PubMed ID: 32650830)
1. Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma.
Xie XH; Wang LQ; Qin YY; Lin XQ; Xie ZH; Liu M; Zhang JX; Ouyang M; Liu J; Gu YY; Li SY; Zhou CZ
Orphanet J Rare Dis; 2020 Jul; 15(1):183. PubMed ID: 32650830
[TBL] [Abstract][Full Text] [Related]
2. Tumor Mutation Burden and Checkpoint Immunotherapy Markers in NUT Midline Carcinoma.
He M; Chernock R; Zhou S; Gondim M; Dehner LP; Pfeifer JD
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):495-500. PubMed ID: 31180909
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case.
Chen M; Chen X; Zhang Y; Wang W; Jiang L
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6361-6370. PubMed ID: 36752907
[TBL] [Abstract][Full Text] [Related]
4. [Utility of NUT gene expression and rearrangement in diagnosis of NUT midline carcinoma in upper respiratory tract].
Fang W; French CA; Cameron MJ; Han YD; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):519-24. PubMed ID: 23157742
[TBL] [Abstract][Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
6. Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients.
Bishop JA; French CA; Ali SZ
Cancer Cytopathol; 2016 Dec; 124(12):901-908. PubMed ID: 27400194
[TBL] [Abstract][Full Text] [Related]
7. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features and long-term outcomes of NUT midline carcinoma.
Bauer DE; Mitchell CM; Strait KM; Lathan CS; Stelow EB; Lüer SC; Muhammed S; Evans AG; Sholl LM; Rosai J; Giraldi E; Oakley RP; Rodriguez-Galindo C; London WB; Sallan SE; Bradner JE; French CA
Clin Cancer Res; 2012 Oct; 18(20):5773-9. PubMed ID: 22896655
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and molecular characterizations of pulmonary NUT midline carcinoma.
Xie M; Fu X; Wang W
Cancer Med; 2021 Sep; 10(17):5757-5764. PubMed ID: 34409758
[TBL] [Abstract][Full Text] [Related]
10. The primary pulmonary NUT carcinomas and some uncommon somatic mutations identified by next-generation sequencing: a case report.
Liu Y; Li YY; Ke XX; Lu Y
AME Case Rep; 2020; 4():24. PubMed ID: 33178996
[TBL] [Abstract][Full Text] [Related]
11. Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations.
Sholl LM; Nishino M; Pokharel S; Mino-Kenudson M; French CA; Janne PA; Lathan C
J Thorac Oncol; 2015 Jun; 10(6):951-9. PubMed ID: 26001144
[TBL] [Abstract][Full Text] [Related]
12. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
[TBL] [Abstract][Full Text] [Related]
13. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
[TBL] [Abstract][Full Text] [Related]
14. The first report of molecular characterized BRD4-NUT carcinoma in Brazil: a case report.
Oliveira LJC; Gongora ABL; Latancia MT; Barbosa FG; Gregorio JVAM; Testagrossa LA; Amano MT; Feher O
J Med Case Rep; 2019 Sep; 13(1):279. PubMed ID: 31492174
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
16. NUT midline carcinoma of the larynx: an international series and review of the literature.
Hellquist H; French CA; Bishop JA; Coca-Pelaz A; Propst EJ; Paiva Correia A; Ngan BY; Grant R; Cipriani NA; Vokes D; Henrique R; Pardal F; Vizcaino JR; Rinaldo A; Ferlito A
Histopathology; 2017 May; 70(6):861-868. PubMed ID: 27926786
[TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
18. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological Analysis of Five Cases of NUT Midline Carcinoma, including One with the Gingiva.
Zhou L; Yong X; Zhou J; Xu J; Wang C
Biomed Res Int; 2020; 2020():9791208. PubMed ID: 32149149
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
